Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;26(3):447-81, vii.
doi: 10.1016/j.hoc.2012.02.013.

Therapeutic antibodies against cancer

Mark J Adler  1 , Dimiter S Dimitrov
Affiliations
Review

Therapeutic antibodies against cancer

Mark J Adler et al. Hematol Oncol Clin North Am. 2012 Jun.

Abstract

Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States. Bevacizumab, rituximab, and trastuzumab had sales in 2010 of more than $5 billion each. Hundreds of mAbs, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized pharmacokinetics, are in clinical trials. However, deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems, and individual variations.

PubMed Disclaimer

References

    1. Dillman RO. Cancer immunotherapy. Cancer biotherapy & radiopharmaceuticals. 2011;26(1):1–64. - PubMed
    1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed
    1. Carter PJ. Potent antibody therapeutics by design. Nat.Rev.Immunol. 2006;6(5):343–357. - PubMed
    1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat.Rev.Drug Discov. 2006;5(2):147–159. - PubMed
    1. Waldmann TA. Immunotherapy: past, present and future. Nat.Med. 2003;9(3):269–277. - PubMed

Publication types

MeSH terms